RxDoctor Payments Data

Lorrie Norman, APRN

Gerontology · Englewood, FLNPI 1346975810

Payments from drug & device makers

$2,058in general payments, 2019–2025

Across 91 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$657
  • Lilly USA, LLC$200
  • GSK$194
  • Takeda Pharmaceuticals U.S.A., Inc.$160
  • Novo Nordisk$146
  • Amgen$128
  • plus $572 from 14 others

What the payments were for

  • Food & beverage$2,03899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,058 in reported general payments places this provider in the 75th percentile of 714 gerontology providers in Florida.

See all gerontology providers in Florida

Medicare billing

Part B allowed, 2024
$49,695
Medicare patients
412
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$53,723
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$35,382
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$19,767
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$18,392
SymbicortBudesonide/Formoterol Fumarate15$5,546
Albuterol Sulfate HfaAlbuterol Sulfate108$2,908
Wixela InhubFluticasone Propion/Salmeterol13$1,256
Fluticasone Propionate35$643
Azelastine Hcl12$599
Levocetirizine Dihydrochloride16$308
Montelukast Sodium12$227
Doxycycline Hyclate14$142
Cefdinir17$139
Prednisone39$117
Famotidine16$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$194$73,49177 claims
AstraZenecaBreztri Aerosphere, Symbicort$657$40,92847 claims
Boehringer IngelheimStiolto Respimat$117$18,39214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 714 gerontology providers in Florida.

Other gerontology in Englewood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →